Schizophrenia/Psychosis

Learn more about the latest advancements in schizophrenia treatment and the ongoing battle against stigma during Mental Health Awareness Month.

Check out the pipeline updates from April!

Peter J. Weiden, MD, discusses the latest Cobenfy data and implications for schizophrenia treatment.

Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.

How can psychiatric professionals and pharmacists best work together to improve patient care? One pharmacist shares his thoughts.

Different medications for different domains: new treatments are changing the way schizophrenia is managed.

Take a look at the differentiation between prodrome and attenuated psychosis, along with cognitive impairment associated with schizophrenia.

Here's what patients should know about Cobenfy for the treatment of schizophrenia.

Peripartum psychosis is considered a psychiatric emergency. Here is how an interdisciplinary team can provide the best care.

Adherence, switching, and quality of life are top concerns in BDI, and schizophrenia.

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.

Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.

The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.

The FDA decision to remove the clozapine REMs requirement has left many questions. Chelsie Monroe, MSN, APN, PMHNP-BC, sheds some light on it.

Chelsea Monroe, MSN, APN, PMHNP-BC, discusses the current renaissance in treating schizophrenia.

Celebrate our 40th anniversary with Gustavo Alva, MD, FAPA, our Mood Disorders Section Editor.

Increased awareness of catatonia and its treatment among health care providers, especially in underresourced areas, is essential for improving patient outcomes.

In a survey capturing the lived experiences of individuals with schizophrenia on antipsychotic medications, 27% of participants reported that antipsychotics had done “more harm than good.”

Postpartum psychosis occurs in about 1 to 2 per thousand new mothers. In this personal story, one writer shares her experience with postpartum psychosis.

Do you want to be featured in a future Special Report? Check out our March theme!

The president of Black Psychiatrists of America shares his thoughts on making a difference for Black communities, the removal of the REMS for clozapine, and more.

A new study from Mount Sinai Health System and IBM Research is investigating the use of AI in developing objective measures for psychiatric diagnoses.

Determining risks outweigh the benefits, the FDA is removing the clozapine REMS requirement.

Cannabis use disorder and schizophrenia both peak in prevalence around the same age. Is there a cause-and-effect relationship?